Climb Bio Inc CLYM
Set alert
10.25 USD -0.08 -0.77%
At close · Oct 30
10.25 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
10.02 Day range 10.51
1.64 52-week range 17.84
- YTD
- +156.25%
- 1 year
- +415.08%
- Open
- 10.29
- Prev close
- 10.33
- Mkt cap
- 588.72M
- Vol
- 708.75K
- Avg vol
- 1.41M
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.02
- High
- 10.51
- Forward P/E
- -16.92
- Beta
- 0.08
- Short ratio
- 5.77
- Inst. own
- 105.23%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 13.42
- 200-d avg
- 8.11
- 1y target
- 22.86
5D chart
Signals (78)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:35 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:40 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 2 days ago |
| RSI: Overbought | Oct 29, 10:00 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:10 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 12:10 PM | 4 days ago |
| RSI: Overbought | Oct 27, 11:00 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| RSI: Oversold | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:55 PM | 5 days ago |
| RSI: Oversold | Oct 26, 1:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 5 days ago |
| RSI: Oversold | Oct 26, 10:55 AM | 5 days ago |
Key statistics
- Market cap
- 1.02B
- Enterprise value
- 760.15M
- Trailing P/E
- 0.00
- Forward P/E
- -16.92
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.28
- EPS (TTM)
- -0.82
- Beta
- 0.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -33.99M
- Total cash
- 183.12M
- Total debt
- 1.31M
- Return on equity
- -27.10%
- Shares outstanding
- 57.44M
- Short % of float
- 17.28%
- 50-day average
- 13.42
- 200-day average
- 8.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 22.86 +123.0% upside
Now 10.25
- Target (low)
- 18.00
- Target (mean)
- 22.86
- Target (high)
- 35.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.195.
Financials — quick view
CLYM Revenue — quarterly 0
CLYM Net income — quarterly -13.50M
CLYM EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.21 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.20931 | -0.18 | +0.03 | +14.00% |
| May 7, 2026 | Mar 31, 2026 | -0.26 | -0.20 | +0.06 | +23.08% |
| Mar 5, 2026 | Dec 31, 2025 | -0.20 | -0.26 | -0.06 | -30.00% |
| Nov 6, 2025 | Sep 30, 2025 | -0.16 | -0.19 | -0.03 | -18.75% |
| Aug 12, 2025 | Jun 30, 2025 | -0.19 | -0.13 | +0.06 | +31.58% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 19, 2026 | Wedbush | reit | Outperform | Outperform |
| Aug 7, 2026 | Truist Securities | main | Buy | Buy |
| Jul 27, 2026 | Wedbush | main | Outperform | Outperform |
| Jun 24, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2026 | Wedbush | reit | Outperform | Outperform |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- climbbio.com
News
- Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN
- Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027
- Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
- Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
- Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
- Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
- HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30
- B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
- BTIG Maintains Buy on Climb Bio, Raises Price Target to $32
- Baird Maintains Outperform on Climb Bio, Raises Price Target to $25
Your note
Sign in to keep a note on CLYM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRENNAN AOIFE M | Chief Executive Officer | Sale | Jun 28, 2026 | 87,731 |
| PIMBLETT EMILY | Officer | Sale | Jun 19, 2025 | 18,888 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 4, 2026 | 0 |
| THOMAS STEPHEN BASIL | Director | Sale | Feb 25, 2026 | 154,657 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 19.68% | 11,300,939 | 201.61M | Jun 29, 2026 |
| FMR, LLC | 11.82% | 6,790,364 | 121.14M | Jun 29, 2026 |
| UBS Group AG | 5.93% | 3,404,866 | 60.74M | Jun 29, 2026 |
| Braidwell LP | 4.87% | 2,797,375 | 49.91M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 4.36% | 2,506,000 | 44.71M | Jun 29, 2026 |
| Blackrock Inc. | 4.10% | 2,354,872 | 42.01M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. | 2.56% | 1,468,417 | 26.20M | Mar 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.74% | 996,857 | 17.78M | May 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.73% | 996,400 | 17.78M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.60% | 920,068 | 16.41M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.49% | 854,986 | 15.25M | Mar 30, 2026 |
| Columbia Funds Series Trust I-Columbia Small Cap Growth Fund | 0.94% | 537,698 | 9.59M | May 30, 2026 |